

# 1 DRUG-RESISTANT TUBERCULOSIS CASE-FINDING STRATEGIES: A SCOPING REVIEW

## 2 PROTOCOL

3 Susanna S van Wyk

4 Centre for Evidence Based Health Care, Division of Epidemiology and Biostatistics,

5 Department of Global Health, Stellenbosch University, Cape Town, South Africa

6 [susanvanwyk@sun.ac.za](mailto:susanvanwyk@sun.ac.za)

7 Marriott Nliwasa

8 Helse Nord Tuberculosis Initiative, Kamuzu University of Health Sciences, Blantyre,

9 Malawi

10 [mnlwasa@gmail.com](mailto:mnlwasa@gmail.com)

11 James A Seddon

12 Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of

13 Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

14 Department of Infectious Diseases, Imperial College London, London, United

15 Kingdom

16 [james.seddon@imperial.ac.uk](mailto:james.seddon@imperial.ac.uk)

17 Graeme Hoddinott

18 Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of

19 Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

20 [graemeh@sun.ac.za](mailto:graemeh@sun.ac.za)

21 Lario Viljoen

22 Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of

23 Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

24 [lario@sun.ac.za](mailto:lario@sun.ac.za)

25 Emmanuel Nepolo

26 Department of Human, Biological and Translational Medical Science, School of  
27 Medicine, University of Namibia, Windhoek, Namibia  
28 [enepolo@unam.na](mailto:enepolo@unam.na)

29 Gunar Günther  
30 Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University  
31 of Bern, Bern, Switzerland  
32 Department of Human, Biological & Translational Medical Science, School of  
33 Medicine, University of Namibia, Windhoek, Namibia  
34 [gunarguenther@gmx.de](mailto:gunarguenther@gmx.de)

35 Nunurai Ruswa  
36 Clinical and Programmatic Coordinator for Drug Resistant Tuberculosis, Ministry of  
37 Health and Social Services, Windhoek, Namibia  
38 [ncruswa@gmail.com](mailto:ncruswa@gmail.com)

39 Hsien-Ho Lin  
40 Institute of Epidemiology and Preventive Medicine, National Taiwan University,  
41 Taiwan  
42 [hsienho@g.ntu.edu.tw](mailto:hsienho@g.ntu.edu.tw)

43 Stefan Niemann  
44 Molecular and Experimental Mycobacteriology Group and National Reference  
45 Center for Mycobacteria, Forschungszentrum Borstel, Germany  
46 [stniemann@yahoo.de](mailto:stniemann@yahoo.de)

47 Neel Gandhi  
48 Departments of Epidemiology and Global Health, Rollins School of Public Health,  
49 Emory University, Atlanta, USA  
50 [neel.r.gandhi@emory.edu](mailto:neel.r.gandhi@emory.edu)

51 Sarita Shah

52 Departments of Epidemiology and Global Health, Rollins School of Public Health,  
53 Emory University, Atlanta, USA  
54 [sarita.shah@emory.edu](mailto:sarita.shah@emory.edu)

55 Mareli Claassens (Corresponding author)

56 Department of Human, Biological and Translational Medical Science, School of  
57 Medicine, University of Namibia, Windhoek, Namibia  
58 Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of  
59 Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa  
60 [mcla@sun.ac.za](mailto:mcla@sun.ac.za)

61 Mailing address:

62 University of Namibia, Private Bag 13301, Windhoek, Namibia

## 63 **ABSTRACT**

### 64 **Background**

65 Transmission of drug-resistant tuberculosis (TB) is ongoing, and many households face  
66 catastrophic costs when a member is diagnosed and treated for drug-resistant TB. Finding  
67 individuals with drug-resistant TB and initiating treatment as early as possible is important to  
68 improve patient clinical outcomes and to break the chain of transmission to help control the  
69 pandemic.

70 To our knowledge systematic reviews assessing effectiveness, cost-effectiveness,  
71 acceptability and feasibility of different drug-resistant TB case-finding strategies to inform  
72 research, policy and practice, have not been conducted and it is unknown whether enough  
73 research exists to conduct such reviews. It is also unknown whether case-finding strategies  
74 are similar for drug-resistant TB and drug-susceptible TB and whether we can draw on  
75 findings from drug-susceptible reviews to inform decisions on drug-resistant TB case-finding  
76 strategies.

## 77 **Methods**

78 The question for our review is: what literature is available on drug-resistant TB case finding  
 79 and which case-finding strategies are described? We will look at studies that have sought to  
 80 improve drug-resistant TB case detection. We will search the academic databases of  
 81 CENTRAL, MEDLINE and EMBASE using no language or date restrictions. We will apply broad  
 82 criteria for screening titles, abstracts and full text articles. A data extraction form will be  
 83 developed in excel and applied to all primary research reports to collect standard  
 84 information on each study. We will provide a narrative report with supporting figures and/or  
 85 tables to summarize the data. A systems-based logic model, developed from a synthesis of  
 86 drug-susceptible TB case-finding strategies, will be used as a framework to describe different  
 87 strategies, resulting pathways and enhancements of pathways.

## 88 **Discussion**

89 This scoping review will chart existing literature on drug-resistant TB case finding and  
 90 identify priority question(s) for a systematic review. It will also describe drug-resistant TB  
 91 case-finding strategies and how they fit into a model of drug-susceptible TB case-finding  
 92 pathways. The review will guide further research to inform decisions on drug-resistant TB  
 93 case finding policy and practice.

## 94 **KEYWORDS**

95 Tuberculosis, drug-resistant tuberculosis, drug-resistant tuberculosis case finding, drug-  
 96 resistant tuberculosis case detection, drug-resistant tuberculosis screening

## 97 **BACKGROUND**

98 With the emergence of *Mycobacterium tuberculosis* (*M. tb*) strains resistant to first line anti-  
 99 tuberculosis drugs, strategies to control tuberculosis (TB) became even more challenging.<sup>1</sup> It  
 100 is estimated that almost half a million people developed rifampicin-resistant (RR) TB, of  
 101 which 78% had multidrug-resistant TB (MDR-TB) in 2019.<sup>2</sup> Although drug-resistant TB is not

102 as prevalent as drug-susceptible TB, it is more difficult to diagnose, treatment is longer and  
103 more toxic, outcomes are worse and costs are higher. Sixty-seven to 100% of people with  
104 drug-resistant TB in their households face catastrophic costs (total costs equivalent to >20%  
105 of annual household income).<sup>2</sup>

106 Finding individuals with drug-resistant TB and initiating treatment as early as possible is  
107 important to improve patient clinical outcomes and to break the chain of transmission to  
108 help control the pandemic. But despite new diagnostic technologies, only 38% of the  
109 estimated number of people who developed drug-resistant TB initiated treatment in 2019.<sup>2,3</sup>  
110 TB can be detected following the patient presenting passively to health services or following  
111 one of several different screening pathways depending on the case-finding strategy of a TB  
112 programme.<sup>4</sup> Pathways can also be enhanced via several activities such as health promotion  
113 in the community, improved access to TB diagnostic services or training of health workers to  
114 identify presumptive TB at general health services. Multiple activities often result in complex  
115 interventions and heterogeneous trials which are difficult to meta-analyse in systematic  
116 reviews.<sup>5,6</sup>

117 To our knowledge systematic reviews assessing effectiveness, cost-effectiveness,  
118 acceptability and feasibility of different drug-resistant TB case-finding strategies to inform  
119 research, policy and practice, have not been conducted and it is unknown whether enough  
120 research exists to conduct such reviews. It is also unknown whether case-finding strategies  
121 are similar for drug-resistant TB and drug-susceptible TB and whether we can draw on  
122 findings from drug-susceptible reviews to inform decisions on drug-resistant TB case-finding  
123 strategies.

124 We will therefore conduct a scoping review to chart existing literature on drug-resistant TB  
125 case finding and identify priority question(s) for a systematic review.<sup>7,8</sup> We will also describe  
126 existing strategies and how they fit into a model of drug-susceptible TB case-finding  
127 pathways.

## 128      **METHODS**

129      The Arksey and O'Malley framework<sup>9,10</sup>, the Joanna Briggs Institute scoping review  
130      methodology<sup>8</sup> and the PRISMA extension for scoping reviews (PRISMA-ScR)<sup>11</sup> will guide  
131      methods for this scoping review.

### 132      **Defining the research question**

133      The question for our review is: what literature is available on drug-resistant TB case finding  
134      and which case-finding strategies are described? We will look at studies that have sought to  
135      improve drug-resistant TB case detection.

### 136      **Identifying relevant studies**

137      We will use the following eligibility criteria:

#### 138      ***Inclusion criteria***

##### 139      •      **Participants**

140      Participants can be any age or gender. They can be people receiving an intervention or  
141      providers of an intervention.

##### 142      •      **Concept**

143      Intervention strategies aiming to improve or enhance participants' pathway(s) to drug-  
144      resistant TB case detection specifically. Intervention strategies aiming to improve TB  
145      case finding in general and only report on the yield of drug-resistant TB cases will be  
146      excluded.

##### 147      •      **Context**

148      Studies conducted at primary care, secondary care, tertiary care or community settings.

149      We will exclude studies that are purely laboratory based, but will include studies where  
150      screening of sputum samples is part of an intervention to improve drug-resistant TB case  
151      finding.

##### 152      •      **Study designs**

153 Systematic reviews, excluding narrative reviews. Primary studies irrespective of study  
 154 design. Qualitative studies, where the experiences of individuals who receive the  
 155 intervention or those who provide the intervention are investigated. We will include  
 156 studies of diagnostic test accuracy if the study describes a drug-resistant TB screening  
 157 strategy and we will include trials comparing different screening or diagnostic tools  
 158 within case-finding interventions. We will exclude prevalence surveys, except if the  
 159 survey includes an intervention strategy to find drug-resistant TB cases specifically. We  
 160 will exclude editorials, opinion articles, meeting summaries and guidelines.

161 We will search the academic databases of Medline (PubMed), Embase (Ovid), The Cochrane  
 162 Library, Africa-Wide Information (EBSCOhost), CINAHL (EBSCOhost), Epistemonikos and  
 163 PROSPERO using no language or date restrictions. Reference lists of included studies will be  
 164 searched.

165 The preliminary search string will include combinations of the following three domains:

- 166 • terms related to “tuberculosis”
- 167 • terms related to “drug resistance”
- 168 • terms related to “case finding”, “case detection”, “screening”, “contact investigation”  
 169 and “contact tracing”

170 Appropriate MesH terms will be added to the different databases. The search strategy will  
 171 be piloted and refined in consultation with an information specialist. We will also contact  
 172 experts working in the field to collect information about ongoing primary research or  
 173 relevant research missed by the electronic search.

#### 174 **Study selection**

175 We will use Rayyan systematic review software <sup>12</sup> to screen titles, abstracts and full text  
 176 articles. Four reviewers (SvW, MN, LV and MC) will screen abstracts in duplicate for  
 177 inclusion. They will resolve conflicts via discussion and meet at the beginning and midpoint  
 178 of abstract screening to discuss challenges and possible refinement of the search strategy.

179 Three reviewers (SvW, LV and MN) will then screen full text articles for inclusion.

180 Disagreements will be resolved with a third reviewer (MC) to determine final inclusion.

## 181 **Charting the data**

182 We will develop a data extraction form in excel. The data extraction form will be applied to

183 all primary research reports to collect standard information on each study. Information will

184 include:

- 185 • Authors, journal, year of publication
- 186 • Aim/purpose of the research
- 187 • Study design
- 188 • Country: income, TB prevalence, human immunodeficiency virus (HIV) prevalence;
- 189 urban/rural setting
- 190 • Participants: age, sex, HIV status, other reported risk factors
- 191 • Target group and how the group was identified if applicable
- 192 • Intervention(s): All components (activities) of the intervention, type(s) of providers and
- 193 screening and diagnostic tools used
- 194 • Treatment support, including preventive therapy
- 195 • Outcomes assessed

196 Five authors (SvW, MN, LV, MC and GH) will extract data, one author per paper. A second  
 197 reviewer (SvW/MC) will check extracted data from each study. The data extraction team and  
 198 other co-authors will meet regularly after each 5-10 studies to determine whether their  
 199 approach is consistent and in line with the research question.

## 200 **Collating, summarizing and reporting the results**

201 We will provide a narrative report with supporting figures and/or tables to summarize the  
 202 data. Table 1 contains definitions we will use in charting, collating, summarizing and  
 203 reporting our results.



204 **Table 1: Definitions**

<b>Drug-resistant TB</b>	All types of drug-resistant TB: single drug-resistant TB, multidrug-resistant TB, extensively drug-resistant TB and any other drug-resistant TB reported by the authors.
<b>Systematic screening for active TB</b>	"The systematic identification of people with suspected (presumptive) active TB, in a predetermined target group, using tests, examinations or other procedures that can be applied rapidly. Among those screened positive, the diagnosis needs to be established by one or several diagnostic tests and additional clinical assessments, which together have high accuracy." <sup>3</sup>
<b>A screening tool</b>	Tests, examinations or other procedures used for systematic screening for active TB. Examples of TB screening tools include a structured symptom-based questionnaire, chest radiography (CXR), or an algorithm. <sup>4</sup> Algorithms may include sequential or parallel tests. With sequential tests, only those who screen positive with the initial test receive a second test. With parallel tests, those who screen positive on any of the tests are regarded as screen positives.
<b>A diagnostic tool</b>	Tests, examinations or other procedures used to establish a diagnosis of TB in people identified with presumptive TB. Examples of TB diagnostic tools include a clinical algorithm, sputum smear microscopy, Xpert MTB/RIF or culture. <sup>4</sup>
<b>TB symptom(s)</b>	Any TB symptom, e.g. cough, fever, night sweats, weight loss or combination of TB symptoms as defined by the study authors.
<b>Care seeking</b>	People seeking care for a perceived health problem.
<b>TB care seeking</b>	People seeking care for TB symptoms specifically.
<b>A risk group</b>	Any group of people in whom the prevalence or incidence of TB is significantly higher than in the general population. Examples of risk groups include a whole population within a geographical area or TB contacts. <sup>3</sup>
<b>A clinical risk group</b>	Individuals diagnosed with a specific disease or condition that increases their risk for TB, e.g. people living with HIV (PLHIV).
<b>Presumptive TB</b>	Presumptive TB is identified when a provider identifies a patient with suspected active tuberculosis. In the context of screening, a person who screens positive is a presumptive TB case.
<b>Passive case finding</b> <b>Passive case finding with an element of systematic screening</b> <b>Triage</b> <b>Enhanced case finding</b> <b>Active case finding</b> <b>Contact tracing/ contact investigation</b> <b>Intensified case finding</b>	*Some of these definitions overlap and are used inconsistently within the literature. We will therefore use our logic model (Fig 1) to clearly describe pathways rather than labelling them with these terms.
* Van Wyk SS, Medley N, Young T and Oliver S. Repairing boundaries along pathways to tuberculosis case detection: An evidence synthesis. Work submitted for publication, June 2021.	

205 A systems-based logic model developed from a synthesis of drug-susceptible TB case-finding  
206 strategies (Figure 1) will be used as a framework to describe different strategies and  
207 resulting pathways. Enhancements of pathways will also be described and may include  
208 enhanced care seeking (e.g. health promotion), improved access to care for those seeking  
209 care (e.g. mobile clinics), improved access to TB screening (e.g. incentives), improved  
210 identification of presumptive TB by health workers (e.g. training of health workers,  
211 incentives) and improved access to TB diagnostic services for individuals identified with  
212 presumptive TB (e.g. transport, sputum collection in the community, mobile laboratory). For  
213 screening pathways we will report on target groups and screening and diagnostic tools used.  
214 Quality appraisal will not be conducted, because this is a scoping review and our interest is  
215 in the existing evidence base, regardless of study design and quality.

## 216 **DISCUSSION**

217 This scoping review will chart existing literature on drug-resistant TB case finding and  
218 identify priority question(s) for a systematic review. It will also describe drug-resistant TB  
219 case-finding strategies and how they fit into a model of drug-susceptible TB case-finding  
220 pathways.

### 221 **Strengths and limitations**

222 Our multidisciplinary review team consists of researchers with extensive experience in TB  
223 related research and the conduct of systematic reviews and qualitative evidence synthesis.  
224 Their experience would be invaluable in collating and summarizing diverse literature in a  
225 sensible way. Another strength is the use of a systems-based logic model that was  
226 developed from a synthesis of drug-susceptible TB case-finding strategies. The model will  
227 help us to construct meaningful pathway descriptions for possible comparisons in future  
228 research and to assess whether drug-resistant TB case-finding pathways are similar to drug-  
229 susceptible pathways.

230 One limitation to the review is the diverse and inconsistent use of intervention terminology  
231 within the literature, which may result in missing relevant studies. Although we cannot  
232 overcome this problem in full, we will work with an information specialist to pilot and  
233 optimize our search strategy and we will discuss potential refinement of our search at  
234 regular meetings during the screening phase. Poor reporting of intervention strategies may  
235 also cause misunderstanding and misclassification of interventions. However, we do not  
236 assess effectiveness as an outcome and therefore bias due to misclassification will be a  
237 minor issue. Lastly, drug-resistant TB case-finding strategies may not fit into a model  
238 developed from drug-susceptible strategies. Nevertheless, such a situation will provide an  
239 opportunity to refine the model for future research.

## 240 Conclusion

241 This scoping review will chart the existing body of literature on drug-resistant TB case-  
242 finding strategies and will guide further research to inform decisions on drug-resistant TB  
243 case finding policy and practice.

## 244 LIST OF ABBREVIATIONS

245 **TB:** tuberculosis

246 ***M. tb:*** *Mycobacterium tuberculosis* (*M. tb*)

247 **RR:** rifampicin-resistant

248 **MDR-TB:** multidrug-resistant tuberculosis

249 **PRISMA-ScR:** PRISMA extension for scoping reviews

250 **HIV:** human immunodeficiency virus

251 **PLHIV:** people living with human immunodeficiency virus

## 252 DECLARATIONS

### 253 Ethics approval and consent to participate

254 Not applicable

### 255 Consent for publication

256 Not applicable

### 257 Availability of data and materials

258 Not applicable

### 259 Competing interests

260 The authors declare that they have no competing interests

## 261 **Funding**

262 SvW is supported by the Research, Evidence and Development Initiative (READ-It). READ-It  
263 (project number 300342-104) is funded by UK aid from the UK government; however, the  
264 views expressed do not necessarily reflect the UK government's official policies.

265 MC is supported jointly by the UK Medical Research Council (MRC) and the UK Foreign,  
266 Commonwealth & Development Office (FCDO) under the MRC/FCDO Concordat agreement  
267 and is also part of the EDCTP2 programme supported by the European Union.

## 268 **Authors' contributions**

269 MC and SvW conceived the study idea. SvW drafted the protocol. All authors read and  
270 approved the final protocol.

## 271 **Acknowledgements**

272 Not applicable

## 273 **REFERENCES**

- 274 1. Allué-Guardia A, García JI and Torrelles JB. Evolution of Drug-Resistant Mycobacterium  
275 tuberculosis Strains and Their Adaptation to the Human Lung Environment. Front.  
276 Microbiol. 2021;12:612675. doi: 10.3389/fmicb.2021.612675.
- 277 2. World Health Organization (WHO). Global tuberculosis report 2020. Geneva: World  
278 Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
- 279 3. World Health Organization (WHO). Consolidated guidelines on tuberculosis. Module 2:  
280 Screening -systematic screening for tuberculosis disease. Geneva: World Health  
281 Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.
- 282 4. World Health Organization (WHO). Systematic screening for active tuberculosis: an  
283 operational guide. Geneva: World Health Organization; 2015. WHO/HTM/TB/2015.16.
- 284 5. Heuvelings CC, de Vries SG, Greve PF, Visser BJ, Bélard S, Janssen S, et al. Effectiveness of  
285 interventions for diagnosis and treatment of tuberculosis in hard-to-reach populations in

- 286 countries of low and medium tuberculosis incidence: a systematic review. *Lancet Infect*  
287 *Dis.* 2017;17:e144-58.
- 288 6. Mhimbira FA, Cuevas LE, Dacombe R, Mkopi A, Sinclair D. Interventions to increase  
289 tuberculosis case detection at primary healthcare or community level services. *Cochrane*  
290 *Database Syst Rev.* 2017;11(CD011432).
- 291 7. Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A and Aromataris E. Systematic  
292 review or scoping review? Guidance for authors when choosing between a systematic or  
293 scoping review approach. *BMC Medical Research Methodology.* 2018;18:143.
- 294 8. Peters MDJ, Godfrey CM, Khalil H, McInerney P, Parker D and Soares CB. Guidance for  
295 conducting systematic scoping reviews. *Int J Evid Based Healthc.* 2015;13:141-6.
- 296 9. Arksey H and O'Malley L. Scoping Studies: Towards a Methodological Framework. *Int. J.*  
297 *Social Research Methodology.* 2005;8(1):19-32.
- 298 10. Levac D, Colquhoun H and O'Brien KK. Scoping studies: advancing the methodology.  
299 *Implementation Science.* 2010;5:69.
- 300 11. Tricco, AC, Lillie, E, Zarin, W, O'Brien, KK, Colquhoun, H, Levac, D, Moher, D, Peters, MD,  
301 Horsley, T, Weeks, L, Hempel, S et al. PRISMA extension for scoping reviews (PRISMA-  
302 ScR): checklist and explanation. *Ann Intern Med.* 2018;169(7):467-473.
- 303 12. Mourad Ouzzani, Hossam Hammady, Zbys Fedorowicz, and Ahmed Elmagarmid. Rayyan  
304 — a web and mobile app for systematic reviews. *Systematic Reviews* (2016) 5:210.

## 305 FIGURES, TABLES AND ADDITIONAL FILES

### 306 **Figure 1: A systems-based logic model depicting types of services and associated pathways** 307 **to TB case detection**

308 The model distinguishes six pathways to TB case detection, namely two care-seeking  
309 pathways (green and black dashed lines) and four screening pathways (green, blue, orange  
310 and grey solid lines). People perceiving themselves to have a health problem and access

311 general health services, follow the general care-seeking pathway where a provider can  
 312 identify presumptive TB on routine assessment, i.e., history taking and clinical examination,  
 313 of an individual patient (green dashed line). People perceiving themselves to have TB  
 314 symptoms may also follow the specific TB care-seeking pathway to TB diagnostic services,  
 315 where all people accessing care are evaluated for possible active TB (black dashed line).  
 316 People invited to TB services regardless of symptoms follow TB screening pathways and may  
 317 be identified with presumptive TB even if they do not seek care for TB symptoms. Four  
 318 screening pathways are distinguished: TB screening offered to all people accessing general  
 319 health services (green solid line), dedicated TB screening services at a health facility or  
 320 mobile clinic with open invitation to a whole population or TB contacts (blue solid line), TB  
 321 screening offered to target group members at home, work or school (orange solid line) and  
 322 TB screening offered to people living with HIV linked to care (grey solid line). A person who  
 323 screens positive on the TB screening pathway is identified as a presumptive TB case and  
 324 should receive confirmation of a diagnosis by accessing TB diagnostic services.

# 325 **Additional file 1**

326 The PRISMA-P Checklist

